2nd Drug Study

download 2nd Drug Study

of 3

Transcript of 2nd Drug Study

  • 7/27/2019 2nd Drug Study

    1/3

    Name Indications Classifications Side Effects Contraindications Nursing

    Considerations

    Cefuroxime

    750mg IV

    It is effective for the

    treatment of

    penicillin ase-producing

    Neisseria gonorrhoea

    (PPNG). Effectively

    treats bone and joint

    infections, bronchitis,

    meningitis,

    gonorrhea, otitis

    media,

    pharyngitis/tonsillitis,

    sinusitis, lower

    respiratory tractinfections, skin and

    soft tissue infections,

    urinary tract

    infections, and is

    used for surgical

    prophylaxis, reducing

    or eliminating

    infection.

    ANTIINFECTIVE;

    ANTIBIOTIC;

    SECOND-GENERATION

    CEPHALOSPORIN

    Body as a Whole:

    Thrombophlebitis (IV

    site); pain, burning,cellulitis (IM site);

    superinfections,

    positive Coombs'

    test.

    GI:

    Diarrhea,

    nausea, antibiotic-

    associated colitis.

    Skin:Rash, pruritus,

    urticaria.

    Urogenital:

    Increased serum

    creatinine and BUN,

    decreased creatinine

    clearance.

    Hypersensitivity to

    cephalosporins and

    related antibiotics;pregnancy

    (category B),

    lactation

    >Determine history

    of hypersensitivity

    reactions tocephalosporins,

    penicillins, and

    history of allergies,

    particularly to drugs,

    before therapy is

    initiated.

    >Inspect IM and IV

    injection sites

    frequently for signs

    of phlebitis.

    >Report onset of

    loose stools or

    diarrhea. Although

    pseudo membranous

    colitis.

    >Monitor I&O rates

    and pattern:

    Especially importantin severely ill patients

    receiving high doses.

    Report any significant

    changes.

  • 7/27/2019 2nd Drug Study

    2/3

    Name Indications Classifications Side Effects Contraindications Nursing

    Considerations

    Ketorelac

    (Toradol)

    IM 30mg/amp1 amp

    Short term

    management of pain

    (not to exceed 5 daystotal for all routes

    combined)

    Ophthalmic: relief of

    ocular itching due to

    seasonal

    conjunctivitis and

    relief of post-

    operative

    inflammation after

    cataract surgery.

    Nonsteroidal

    anti-inflammatory

    agents, nonopioidanalagesics

    CNS:

    Drowsiness

    abnormal thinkingdizziness

    euphoria

    headache-

    - RESP:

    asthma

    dyspnea

    - CV:

    edema

    pallor

    vasodilation

    - GI:GI Bleeding

    abnormal taste

    diarrhea

    dry mouth

    dyspepsia

    GI pain

    nausea

    - GU:

    oliguria

    renal toxicityurinary frequency

    Hypersensitivity

    - Cross-sensitivity

    with other NSAIDsmay existPre- or

    perioperative use

    - Known alcohol

    intoleranceUse

    cautiously in:

    1) History of GI

    bleeding

    2) Renal impair-ment

    (dosage reduction

    may be required)

    3) Cardiovasculardisease

    - Patients who have

    asthma, aspirin-

    induced allergy, andnasal polyps are at

    increased risk for

    developing

    hypersensitivity

    reactions. Assess for

    rhinitis, asthma, and

    urticaria.

    - Assess pain (note

    type, location, and

    intensity) prior to

    and 1-2 hr followingadministration.

    - Ketorolac therapy

    should always be

    given initially by the

    IM or IV route. Oral

    therapy should be

    used only as a

    continuation of

    parenteral therapy.

    - Caution patient toavoid concurrent use

    of alcohol, aspirin,

    NSAIDs,

    acetaminophen, or

    other OTC

    medications without

    consulting health

    care professional.

  • 7/27/2019 2nd Drug Study

    3/3